Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Verrica Pharmaceuticals Inc. Common Stock (VRCA)

Pharmaceutical Preparations

https://www.verrica.com

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts.

10 NORTH HIGH STREET, SUITE 200
WEST CHESTER, PA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/15/2018

Market Cap

119,624,682

Shares Outstanding

42,070,000

Weighted SO

42,064,553

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

LIAN --.--%

IVA --.--%

EWTX --.--%

VIGL --.--%

CNTB --.--%

ABOS --.--%

ETON --.--%

NUVB --.--%

ELDN --.--%

Beta

1.5620

Last Div

0.0000

Range

2.7-11.41

Chg

-0.0900

Avg Vol

372066

Mkt Cap

119624682

Exch

NASDAQ

Country

US

Phone

484 453 3300

DCF Diff

2.5170

DCF

0.3930

Div Yield

0.0000

P/S

8.6011

EV Multiple

-1.7307

P/FV

-9.8599

Div Yield %

0.0000

P/E

-1.5085

PEG

0.0182

Payout

0.0000

Current Ratio

2.3599

Quick Ratio

2.2250

Cash Ratio

1.5924

DSO

267.8976

DIO

447.4994

Op Cycle

715.3970

DPO

190.3197

CCC

525.0774

Gross Margin

0.8414

Op Margin

-5.6314

Pretax Margin

-6.2506

Net Margin

-6.2506

Eff Tax Rate

-0.0020

ROA

-1.6715

ROE

-6.9162

ROCE

-2.4507

NI/EBT

1.0000

EBT/EBIT

1.1100

EBIT/Rev

-5.6314

Debt Ratio

0.8422

D/E

-3.2934

LT Debt/Cap

1.4516

Total Debt/Cap

1.4360

Int Coverage

-130.7529

CF/Debt

-1.5033

Equity Multi

-3.9105

Rec Turnover

1.3625

Pay Turnover

1.9178

Inv Turnover

0.8156

FA Turnover

3.2810

Asset Turnover

0.2674

OCF/Share

-1.4160

FCF/Share

-1.4225

Cash/Share

0.6866

OCF/Sales

-4.7345

FCF/OCF

1.0046

CF Coverage

-1.5033

ST Coverage

-62.6518

CapEx Coverage

-217.3168

Div&CapEx Cov

-217.3168

P/BV

-9.8599

P/B

-9.8599

P/S

8.6011

P/E

-1.5085

P/FCF

-1.8084

P/OCF

-1.9915

P/CF

-1.9915

PEG

0.0182

P/S

8.6011

EV Multiple

-1.7307

P/FV

-9.8599

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 05, 07:30 Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma GlobeNewswire Inc. Jan 04, 07:30 Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTHâ„¢ for the Treatment of Common Warts GlobeNewswire Inc. Jan 03, 07:30 Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTHâ„¢ Benzinga Dec 15, 12:46 Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session GlobeNewswire Inc. Nov 09, 07:30 Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results

Revenue Product Segmentation